The relationship of renal function to outcome: A post hoc analysis from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study. [PDF]
, 2017 The ENSURE-AF study (NCT 02072434) of anticoagulation for electrical cardioversion in nonvalvular atrial fibrillation (NVAF) showed comparable low rates of bleeding and thromboembolism between the edoxaban and the enoxaparin-warfarin treatment arms. This
Al-Saady, N +4 more
core +2 more sources
Edoxaban and amiodarone: interactions on multiple levels [PDF]
European Heart Journal, 2015 This editorial refers to ‘Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial’, by J. Steffel et al., on page doi:10.1093/eurheartj/ehv201. Stroke prevention using oral anticoagulation is a highly effective intervention to improve outcomes among patients with atrial fibrillation
openaire +3 more sources
Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial. [PDF]
, 2017 Oral anticoagulation prevents ischemic strokes in patients with atrial fibrillation (AF). Early detection of AF and subsequent initiation of oral anticoagulation help to prevent strokes in AF patients.
Blank, BF +10 more
core +2 more sources
Teendők súlyos vérzés vagy sürgős sebészeti beavatkozás esetén direkt orális antikoaguláns gyógyszerrel kezeltekben. Az új dabigatran-antidótum: idarucizumab helye a klinikai gyakorlatban [PDF]
, 2016 Absztrakt Az elmúlt hat évtizedben csak a K-vitamin-antagonista kumarinokat alkalmazhattuk orális antikoagulánsként.
Boda, Zoltán
core +1 more source
Special considerations for therapeutic choice of non-vitamin K antagonist oral anticoagulants for Japanese patients with nonvalvular atrial fibrillation. [PDF]
, 2017 Nonvalvular atrial fibrillation (AF) is a risk factor for stroke in elderly patients. Although warfarin has been used to prevent AF-associated stroke for more than 50 years, non-vitamin K antagonist oral anticoagulants (NOACs) including dabigatran ...
Alexander +29 more
core +1 more source
CPT: Pharmacometrics & Systems Pharmacology, 2023 This study aimed to develop a physiologically‐based pharmacokinetic pharmacodynamic (PBPK/PD) parent‐metabolite model of edoxaban, an oral anticoagulant with a narrow therapeutic index, and to predict pharmacokinetic (PK)/PD profiles and potential drug ...
Ruijuan Xu +4 more
doaj +1 more source
The role of edoxaban in preventing thromboembolic complications in patients with atrial fibrillation
Атеротромбоз, 2020 Edoxaban is a selective direct factor Xa inhibitor. Edoxaban in a dose of 60 mg per day is an effective and safe option in the prevention of thromboembolic complications in patients with nonvalvular atrial fibrillation, including in combination therapy ...
O. O. Shakhmatova
doaj +1 more source
Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management [PDF]
, 2017 Novel oral anticoagulants (NOACs), which include direct thrombin inhibitor (dabigatran) and direct factor Xa inhibitors (rivaroxaban, apixaban and edoxaban), are gaining popularity in the prevention of embolic stroke in non-valvular atrial fibrillation ...
Cheung, KS, Leung, WK
core +1 more source
Scientific Reports, 2023 Since SLCO1B1 encodes the uptake transporter OATP1B1, which can influence the pharmacokinetic and pharmacodynamic profiles of edoxaban, polymorphisms in SLCO1B1 may affect the edoxaban response.
Ji Min Han +6 more
doaj +1 more source
ChemMedChem, EarlyView.A method is developed and validated to quantify edoxaban in solid oral dosage forms using micellar liquid chromatography. A chemometric strategy is used to study the retention mechanism. The procedure is green, economic, safe, and easy to handle; offers high sample throughput; and is reliable, thus useful for pharmaceutical quality control.
Juan Peris‐Vicente +4 more
wiley +1 more source